Ibrance trial halt threatens Pfizer’s growth targets
One trial of Pfizer’s drug in early breast cancer has been stopped, and expectations dim for another.
Genfit’s predictable liver disease failure sets up a cirrhosis pivot
Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.
The crucial trials Medtronic has had to pause
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Blueprint’s voyage ends in disaster
The failure of a crucial pivotal study consigns Blueprint’s lead drug, Ayvakit, to a tiny niche.
Kevzara's Covid-19 setback shows need for hard evidence
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
Amarin falls at obvious hurdle
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
For Lundbeck’s acquisition strategy bad luck comes in threes
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Setback lays bare Novo’s need in haemophilia
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
Lynparza's surprise stumble could finally bury cediranib
Another trial seems to suggest that adding VEGF blockade to Parp inhibition does little for patients without tumour mutations.
